Abstract: Background: Nanomedicine, defined as the application of nanotechnology for the prevention, cure and diagnosis of diseases, has emerged as one of the most exciting tools in the medical field for direct benefit to human health. Nanomedicine aims to engineer the materials at nanoscale to develop new drugs, delivery systems in a way to mimic or understand the cellular processes at molecular level for therapeutics of diseases. Based on their applications, nanomedicines include nano drug delivery systems, nano-diagnostics, nano-theranostics, and nano-medical implants.
INTRODUCTION
Nanotechnology works at the atomic, molecular, and supra-molecular levels of approximately 1-100 nm scale and is a promising field of science implicated for a range of consumer goods to health products. It has the potential to open up new possibilities for improvement of drug properties i.e. solubility and stability, development of additional proficient methodology in drug delivery systems and offers great prospective in medical imaging, *Address correspondence to this author at the Jan Nayak Ch. Devi Lal Memorial College of Pharmacy, Sirsa, 125055, Haryana, India;
Tel: +91-1666-238114; Fax: +91-1666-238100; E-mail: vinnylather@gmail.com diagnosis, drug targeting, cancer therapy, and regenerative medicine [1] [2] [3] [4] [5] . Nanomedicines integrate nanoparticles to attain improved targeting, reduced toxicity, and enhanced efficacy of therapeutic, biological or diagnostic agents in vivo [6] . Incorporation of existing drugs in nanoparticles facilitates superior pharmacodynamic and/or pharmacokinetic parameters. Global regulatory trends for nanomedicines are undefined so far and therefore, there is a need of closer collaboration amongst regulatory agencies. Alternatively, conventional strategies have been adopted for the development of nanomedicines as well as for their safety and toxicity evaluation [7] . Nevertheless, numerous nanomedicines have received regulatory approval, however, approval of 'nanosimilars' may require different guidelines. Biologics based nanoparticles encountered complexity in replication of products because little alteration in nanoparticle properties might transform the biological impact [8, 9] . According to a research report from the Business Communications Company Research, despite the catastrophic consequences of the 2008-2009 crisis on capital markets, the global nanomedicine sector had grown tremendously [10] . The BCC Research firm has estimated the global nanopharmaceutical market at $209 billion in 2014 and anticipated to expand to $412 billion by 2019. In this context, the term "global market" is defined as the sum of the markets in the USA, Europe (France, Germany, United Kingdom, Belgium, Netherland, Italy, and Spain) and Japan. Further, the market share of nanopharmaceuticals was 15% of the total pharmaceutical market in 2014 and is estimated to grow to 22% in 2019. In addition, the average compound annual growth rate (CAGR) for this class of products is estimated to be 14.5% as opposed to 5.5% for non-nano pharmaceuticals. The oncology sector is the most dominant one amongst the nanopharmaceuticals, representing approximately 35% of the global market [11, 12] . Various key points like applications of nanomedicines, global authorities for their regulation and the recent updates on the nanomedicine based products in the global market will be highlighted in this review.
APPLICATIONS OF NANOMEDICINE IN MEDICAL FIELD
Nanomedicine simply means the medical application of nanotechnology. The size of nanoparticles is comparable to that of nearly all biomolecules and cellular structures; thus, nanoparticles can be useful for both in vivo and in vitro research and applications in biomedical research. Applications of medical nanotechnology span across a variety of areas such as in drug development, drug delivery technologies, medical devices, medicines, therapeutics (in disease's diagnostics, abnormal conditions), surgery, medical robotics, enhanced gene therapy, tissue engineering procedures and in the general sake of increasing knowledge of the human body [13, 14] . Nanotechnology is providing innovative therapeutic opportunities for various therapeutic agents which cannot be used efficiently as conventional oral formulations, owing to their bioavailability problems. Nanotechnology offers amazing prospects to improve materials and medical devices and also to construct novel "smart" technologies and devices where current and more conventional tools may be reaching their limits [15] . Nanomedicine is used for early detection, diagnosis, treatment and prevention of diseases like diabetes, infections, cancer, infectious diseases, eye diseases, Alzheimer's disease, arthritis, cardiovascular diseases like atherosclerosis, musculoskeletal dysfunctions, and many more [16] [17] [18] [19] [20] [21] [22] . Nanomedicine based products can result in noninvasive nano-devices that can enter the body to detect blood glucose levels, differentiate among normal and cancerous cells, and offer genetic screening for numerous disorders. Applications of nanomedicine in cardiovascular disorders include early detection and treatment of atherosclerosis and decreasing re-stenosis rates after stenting. The term "nano-theranostics" may be defined as a methodology that combines simultaneously the modalities of the therapeutic and diagnosis in a nano-carrier. The nano-theranostics based nanomedicines can reach systemic circulation, evade host defense system and deliver the medicine as well as diagnostic agents at the targeted location to detect and treat the disorder at the cellular and molecular level. The various applications of nanotechnology in medicine (including both therapy and diagnosis of diseases) are presented in Fig. (1) [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] .
SAFETY, QUALITY AND REGULATORY ASPECTS OF NANOMEDICINES
Despite the tremendous advancements in the field of nanotechnology, it poses several potential risks which can be broadly classified as: the risk to health and environment from nanoparticles and nanomaterials; the risk posed by molecular manufacturing; and the risk to society. Nanotechnology relates to distinctive properties of materials on a nano-scale leading to greater risk for major instability at atomic and molecular levels resulting in increased risk of damage at cellular level [23] . Despite the many proposed advantages of nanoparticles, growing concerns have been expressed on their potential adverse effects on human health. As nanoparticles have different physicochemical characteristics than their fine-sized analogues due to their extremely small particle size and more surface area, they need to be evaluated separately for toxicity and adverse effects on health. In addition, in the field of nanomedicine, subcutaneous and intravenous injections of nanomedicine based carrier systems deliver exogenous nanoparticles directly into the human body exclusive of passing through the usual absorption route. These nanomedicine based carrier systems themselves could be liable for the toxicity and interaction with the biological macromolecules. Next, insoluble nanomedicine based carrier systems may perhaps accumulate in cells, tissues or organs. Therefore, it is mandatory to deal with the potential health and safety implications of nanomaterials used in nanomedicine [24] . Subsequently, the manufacturing and application of nano-materials are growing extensively resulting in increased production and consumption of nanomaterials. Human beings can be exposed through various ways including breathing, ingestion, and penetration across the skin. An important challenge for scientists, industries, and regulatory agencies is how to categorize the novel materials and what further analysis regarding toxicity and safety is mandatory before these products become available in the market [25] .
Applications of nanotechnologies and incorporation of nanomaterials in medicines are growing and several novel products, currently in development are expected to enter the market in the near future. Therefore, it is becoming increasingly important to have regulatory frameworks that properly address and specifically manage the potential risks of nanotechnology. Pharmaceutical regulatory agencies and organizations around the world for technical and regulatory perspectives/guidance for nanomedicines are United States Food and [26] https://www.pharmatutor.org/articles/pharmaceutical-regulatory-agencies-and-organizationsaround-world-scope-challenges-in-drug-development. Nanotechnology standardization for electrical and electronic products and systems has initiated a line of activities through working groups towards harmonizing standards that focus on the WG1 Terminology and nomenclature led by Canada; WG 2 Measurement and characterization led by Japan; WG 3 HSE led by the USA; and WG 4 Material Specifications led by China [27] . The most important aspects regarding safety, quality and regulation of nanotechnology-based products used in medicine for different parts of the world are represented in Table 1 . ! EMEA's task, according to its mission statement is "to contribute to the protection and promotion of public and animal health by mobilizing scientific resources from throughout the European Union to provide high-quality evaluation of medicinal products, to advise on research and development programmes and to provide useful and clear information to users and health care professionals developing efficient and transparent procedures, to allow timely access by users to innovative medicines through a single European marketing authorization, and in particular through a pharmacovigilance network and the establishment of safe limits for residues in food producing animals".
[ [35] [36] [37] 3 Australia TGA TGA regulates therapeutic goods (including supplements and sunscreen) and medical devices. Decisions on household chemicals are made by the Secretary to the Department of Health who is advised by a committee formed under the Therapeutic Goods Regulations.
According to the TGA, if nanomaterials are added to existing therapeutic goods, they will require reassessment, and manufacturers must submit or hold safety data on new products. However that requirement does not appear to be reflected in the TGA Regulations, nor do any sunscreens or other therapeutic goods known to contain nanomaterials appear to be listed in the register of Therapeutic Goods.
[ [38] [39] [40] [41] 4 Japan PMDA PMDA is an independent administrative legal authority which is the entry portal for the approval of drugs and medical devices and collaborates with the Ministry of Health, Labour and Welfare (MHLW).
Various laws and regulations provide the basis for pharmaceutical administration in Japan; among them are the Pharmaceutical Affairs Law (PAL), the Law Concerning the Establishment for Pharmaceuticals and Medical Devices Organization, and the Law Concerning Securing Stable Supply of Blood Products.
The Pharmaceutical and Medical Device Act has been launched in Nov 2014 which is entitled as "Act on Securing Quality, Efficacy and Safety of Pharmaceuticals, Medical Devices, Regenerative and Cellular Therapy Products, Gene Therapy Products and Cosmetics".
[42] The Department encourages manufacturers to request a pre-submission meeting with the responsible regulatory authority to discuss the type of information that may be required for their product's safety assessment.
As part of its international collaborative work on nanotechnology and nanomaterials, health Canada is engaged with Environment Canada. Its goal is to share information and develop joint approaches on regulatory aspects of nanomaterials including terminology and nomenclature as well as risk assessment and management.
[43] [1]
7 Brazil ANVISA ANVISA generated in 1999 is an independently administered and financially autonomous regulatory body of the Brazilian government managed by a collegiate board of directors and linked to the Ministry of Health and is the entry portal for the regulation and approval of drugs and medical devices.
In view of this situation, Brazil has started to reform and improve its system such as by means of allowing manufacturers to commence their application process before the Goods Manufacturing Practices (GMP) certificate has been obtained. [44] 8 India CDSCO CDSCO is the national regulatory body and entry portal for regulation and approval of pharmaceuticals and medical devices in India and is linked to the Ministry of Health and Family Welfare and holds six zonal offices, four sub-zonal offices, several port offices and laboratories.
Within the CDSCO, the Drug Controller General of India is the main licensing authority which directly issues permission for new drugs and specific medical devices and for the manufacturing of certain drugs (vaccines, blood-products, r-DNA derived).
[45] In this field, China is in a backlog in comparison with international compliance guidelines and in slow processing of numerous approval applications.
A new classification of pharmaceuticals is being envisaged and Innovative drugs covering an urgent medical need shall be approved by means of "Fast Track".
[46] According to MHRA judgments on safety, quality and performance will be informed by all available, relevant and reliable evidence, with the burden of proof often resting on companies.
Important regulatory checkpoints for any novel medicine include the moment at which permission is given to enter into first-in-man studies, the time of market authorization and not least review of information captured by post-market surveillance.
[48] 
OVERVIEW OF THE NANOMEDICINE BASED PRODUCTS APPROVED WORLD-WIDE
Nanomedicine is a relatively new and rapidly evolving field combining nanotechnology with the biomedical and pharmaceutical sciences. The adoption of nanoscience terminology by pharmaceutical scientists resulted in the advent of nanopharmaceuticals (nanomedicine based products). An overview of various nanotechnology-based products (nanopharmaceuticals or nanomedicine products) approved recently by various regulatory authorities has been presented in Table 2 along with their active molecules, delivery system, applications and route of administration [49] [50] [51] [52] [53] .
CONCLUSION
This review article outlines that nanotechnology is considered to be an innovative industrial reformation and also proved to be helpful in various diseases by improving efficiency and safety in nanomedicines and nanodevices. In medicine, it bestows therapeutics, diagnosis, early detection as well as a preventive indication for a wide range of disorders. The agencies like USFDA and EMEA should initiate to prepare currently for the upcoming revolution in nanomedicine. Nanomedicine is one of the chief tools of the 21 st century with desired prospects for both the researchers and pharmaceutical industry. A strategic approach for evaluation of the toxicity and safety of nano-medicine-based products within the standard set of framework will encourage further research on the technology and stir up the conventional systems for drug delivery. Collaboration among countries around the world is required in order to exchange information and to ensure a high level of protection for humans and the environment, while not hampering the development of new beneficial products and their global marketing. In the interest of all manufacturers, regulatory authorities and consumers, there is a mandatory requirement for an international harmonization for the evaluation of the toxicity and safety of nanomedicine based products.
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